Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Island Pharmaceuticals Secures US Patent for Galidesivir

Island Pharmaceuticals (ASX: ILA) jumped 12 per cent this week after announcing it secured a US patent for galidesivir, its antiviral drug designed to fight some of the world’s deadliest viruses. While a broad US patent protects galidesivir’s use in COVID-19 until July 2042, the company just secured an additional patent yesterday specifically for filoviridae viruses (like Marburg and Ebola). For investors, the timing matters because galidesivir is now moving towards FDA approval through a fast-track pathway that could see it reach the market within the next 12 to 18 months.

What makes this particularly interesting is the potential payoff. If approved, Island Pharmaceuticals could receive a Priority Review Voucher worth over US$100 million, plus ongoing contracts to supply the US government’s emergency stockpiles. For a company with a market cap of around A$124 million, that kind of revenue would be transformational.

What are the Best ASX Biotech Stocks to invest in right now?

Check our buy/sell tips

Why Galidesivir Could Become a Key Weapon Against Deadly Outbreaks

Galidesivir is not just targeting one virus. The drug has shown activity against more than 20 different RNA viruses, including Marburg, Ebola, Zika, and Yellow Fever. Marburg alone kills up to 88 per cent of people who catch it, and there is currently no approved treatment. That gap in global health defences is exactly what Island is trying to fill.

The path to approval is unusual but potentially faster than normal drug development. Under the FDA’s Animal Rule, drugs for diseases like Marburg can be approved based on animal studies rather than human trials. You simply cannot ethically infect humans with Marburg to test a drug, so the FDA allows this alternative. Island has already completed human safety trials, meaning the main hurdle left is proving the drug works in animals. The company plans to run that pivotal study in Q1 2026. The US government has already invested over US$70 million in galidesivir’s development over the years, which tells us biosecurity agencies see real potential here.

The Commercial Opportunity: Government Contracts and Voucher Sales

If galidesivir gets approved, Island stands to benefit in two major ways. First, the FDA awards Priority Review Vouchers to companies that develop treatments for neglected diseases. These vouchers can be sold to big pharma companies, and recent sales have fetched between US$100 million and US$160 million. That is serious money for a micro-cap biotech.

Second, there is the US Strategic National Stockpile. The government keeps emergency supplies of treatments for biological threats, and right now, there is no approved Filoviridae antiviral sitting on those shelves. Annual stockpile contracts for these kinds of drugs can run into the hundreds of millions over time. With the current US policy pushing for domestic biosecurity solutions, Island’s freshly granted patent strengthens its position considerably.

The Investor’s Takeaway for Island Pharmaceuticals

We see Island Pharmaceuticals as a high-risk, high-reward opportunity that only suits investors comfortable with speculation. The patent win and FDA pathway are real catalysts, but the risks are equally real.

Cash is the immediate concern. Island Pharmaceuticals holds approximately A$8 million following a recent A$1 million capital injection from directors, which does not provide much runway. If the company needs to raise capital before hitting its milestones, shareholders could face dilution. There is also the ever-present risk that clinical studies fail, which would undermine the entire investment thesis.

On the upside, successful approval could unlock combined value from voucher sales and government contracts, potentially exceeding US$200 million over time. For speculative investors who understand biotech volatility, Island offers genuine asymmetric upside. More conservative investors may prefer to wait for study results before taking a position.